Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients with non-infectious intermediate or posterior uveitis or panuveitis in at least one eye, age 18 to 70 years of age inclusive, who are otherwise in good health
Macular edema with average central retinal thickness ≥ 250 µm
A vitreous haze score ≥ 1, but ≤ 3 (based on the National Eye Institute grading system)
Best Corrected Visual Acuity no worse than 20/400 and no better than 20/40
3. White dot retino-choroidopathies (e.g., multiple evanescent white dot syndrome (MEWDS) or multifocal choroiditis)
Macular edema associated with other ocular disease (e.g., diabetic retinopathy)
Patients who had a prior vitrectomy
Any eye condition that may affect the evaluation of visual acuity and retinal thickness
Concurrent use of certain immunosuppressive agents (specific washout periods for different agents are defined in the protocol)
Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g. deferoxamine, chloroquine, and ethambutol) currently or in the past 6 months
Clareo Health | Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
